SEC Form 4 · accession 0001857256-26-000006
Gossamer Bio, Inc. · GOSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Caryn Peterson
Officer — Chief Development Officer
Period of report
Aug 24, 2026
Accepted (ET)
Aug 26, 2026 · 6:12 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001728117
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.175 | Aug 24, 2026 | A | 5,800,051 | A | — | Aug 23, 2036 | Common Stock | 5,800,051 | 5,800,051 | D |
Explanation of responses
- F150% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.